Alnylam's gene-silencing drug shows efficacy in late-stage trial

Alnylam Pharmaceuticals Inc said on Thursday its gene-silencing drug for a rare, painful genetic disease was found to be effective in a late-stage trial, putting the firm on track for a faster approval from U.S. regulator.